275 related articles for article (PubMed ID: 34073861)
1. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars in Belgium: a proposal for a more competitive market.
Moorkens E; Vulto AG; Huys I
Acta Clin Belg; 2021 Dec; 76(6):441-452. PubMed ID: 32400319
[TBL] [Abstract][Full Text] [Related]
3. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage.
Maniadakis N; Holtorf AP; Otávio Corrêa J; Gialama F; Wijaya K
Appl Health Econ Health Policy; 2018 Oct; 16(5):591-607. PubMed ID: 29987759
[TBL] [Abstract][Full Text] [Related]
4. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
Front Pharmacol; 2021; 12():644187. PubMed ID: 33953678
[No Abstract] [Full Text] [Related]
5. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
[TBL] [Abstract][Full Text] [Related]
6. Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review.
Vulto AG; Vanderpuye-Orgle J; van der Graaff M; Simoens SRA; Dagna L; Macaulay R; Majeed B; Lemay J; Hippenmeyer J; Gonzalez-McQuire S
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33213079
[TBL] [Abstract][Full Text] [Related]
7. Tendering and biosimilars: what role for value-added services?
Simoens S; Cheung R
J Mark Access Health Policy; 2020; 8(1):1705120. PubMed ID: 32002174
[No Abstract] [Full Text] [Related]
8. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis.
Barcina Lacosta T; Vulto AG; Huys I; Simoens S
Front Pharmacol; 2022; 13():1031910. PubMed ID: 36588696
[No Abstract] [Full Text] [Related]
10. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain.
Barcina Lacosta T; Vulto AG; Huys I; Simoens S
Front Med (Lausanne); 2022; 9():1029040. PubMed ID: 36703896
[TBL] [Abstract][Full Text] [Related]
11. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
12. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
Vogler S; Schneider P; Zuba M; Busse R; Panteli D
Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
[No Abstract] [Full Text] [Related]
13. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
14. Key drivers for market penetration of biosimilars in Europe.
Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
[No Abstract] [Full Text] [Related]
15. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market.
Río-Álvarez I; Cruz-Martos E
Expert Opin Biol Ther; 2024 Jun; ():1-15. PubMed ID: 38842367
[TBL] [Abstract][Full Text] [Related]
16. Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):509-519. PubMed ID: 38284223
[TBL] [Abstract][Full Text] [Related]
17. An international comparative analysis and roadmap to sustainable biosimilar markets.
Alnaqbi KA; Bellanger A; Brill A; Castañeda-Hernández G; Clopés Estela A; Delgado Sánchez O; García-Alfonso P; Gyger P; Heinrich D; Hezard G; Kakehasi A; Koehn C; Mariotte O; Mennini F; Mayra Pérez-Tapia S; Pistollato M; Saada R; Sasaki T; Tambassis G; Thill M; Werutsky G; Wilsdon T; Simoens S
Front Pharmacol; 2023; 14():1188368. PubMed ID: 37693908
[No Abstract] [Full Text] [Related]
18. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.
Curto S; Ghislandi S; van de Vooren K; Duranti S; Garattini L
Health Policy; 2014 Jun; 116(2-3):182-7. PubMed ID: 24602376
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
20. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.
Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
BioDrugs; 2019 Jun; 33(3):285-297. PubMed ID: 30945207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
